Drug Development

Clinical Trials Market Competition Clinical Research Market Trends Market Approval Regulatory Affairs Market Access Market Launch Market Impact FDA Approval

3 ARTICLES

4d ago

FDA Expands Mounjaro Approval to Include Prevention of Heart Attacks and Strokes

The agency’s decision relied on a head-to-head cardiovascular outcomes trial that showed about an 8% relative reduction versus an older GLP-1, prompting broader use and continued safety monitoring.

10 ARTICLES

6d ago

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

7 ARTICLES

last wk.

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

6 ARTICLES

2w ago

FDA Grants Accelerated Approval to Genglycos for Glycogen Storage Disease Type Ia

7 ARTICLES

2w ago

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

6 ARTICLES

last mo.

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

3 ARTICLES

last mo.

Pfizer’s Oral Drug Shows Strong Phase 3 Results in Nonsegmental Vitiligo

3 ARTICLES

last mo.

FDA Approves Lytenava, First Ophthalmic Bevacizumab for Wet AMD

3 ARTICLES

last mo.

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

3 ARTICLES

last mo.

FDA Delays Rivoceranib Approval Citing Manufacturing Compliance at Chinese Plant

3 ARTICLES

last mo.

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

5 ARTICLES

last mo.

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

4 ARTICLES

2mo ago

Lilly Launches Tanstrive as First Selective RET Inhibitor Now Available in India

35 ARTICLES

2mo ago

One 79-Year-Old Granted Compassionate‑Use Access to Eli Lilly’s Unapproved Obesity Drug

7 ARTICLES

2mo ago

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

4 ARTICLES

2mo ago

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

6 ARTICLES

2mo ago

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

Drug Development

FDA Expands Mounjaro Approval to Include Prevention of Heart Attacks and Strokes

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

FDA Grants Accelerated Approval to Genglycos for Glycogen Storage Disease Type Ia

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

AbCellera’s Menopause Antibody Hits Phase 2 Goals

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Pfizer’s Oral Drug Shows Strong Phase 3 Results in Nonsegmental Vitiligo

Never miss stories about

Drug Development

FDA Approves Lytenava, First Ophthalmic Bevacizumab for Wet AMD

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

FDA Delays Rivoceranib Approval Citing Manufacturing Compliance at Chinese Plant

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

Lilly Launches Tanstrive as First Selective RET Inhibitor Now Available in India

One 79-Year-Old Granted Compassionate‑Use Access to Eli Lilly’s Unapproved Obesity Drug

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

Never miss stories about

Drug Development